Back to top
more

Acer Therapeutics (ACER)

(Delayed Data from OTC)

$0.66 USD

0.66
NA

0.00 (0.00%)

Updated Nov 20, 2023 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (147 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Acer (ACER) to Get Acquired by Zevra for $91M, Stock Up

by Zacks Equity Research

Acer (ACER) surges as Zevra Therapeutics offers to acquire it for approximately $91 million.

Acer Therapeutics Inc. (ACER) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Acer Therapeutics Inc. (ACER) closed at $0.76 in the latest trading session, marking a +1.13% move from the prior day.

ACER's Stock Down on Failure of Phase II Study, Cash Updates

by Zacks Equity Research

ACER announces the failure of its phase IIa study of ACER-801 to treat vasomotor symptoms associated with menopause, along with its extinguishing cash runway. Stock down.

Acer Therapeutics Inc. (ACER) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Acer Therapeutics Inc. (ACER) closed the most recent trading day at $1.67, moving -1.76% from the previous trading session.

Acer Therapeutics Inc. (ACER) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Acer Therapeutics Inc. (ACER) closed at $2.16, marking a -0.92% move from the previous day.

Acer Therapeutics Inc. (ACER) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Acer Therapeutics Inc. (ACER) closed at $2.18, marking a +1.87% move from the previous day.

Acer Therapeutics Inc. (ACER) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Acer Therapeutics Inc. (ACER) closed the most recent trading day at $2.09, moving -0.48% from the previous trading session.

Acer (ACER) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Acer Therapeutics' (ACER) fourth-quarter earnings call, investors' focus is likely to be on the company's pipeline development.

Acer Therapeutics Inc. (ACER) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Acer Therapeutics Inc. (ACER) closed at $2.28 in the latest trading session, marking a -1.72% move from the prior day.

Acer Therapeutics Inc. (ACER) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Acer Therapeutics Inc. (ACER) closed at $2.40, marking a +1.27% move from the previous day.

Acer Therapeutics Inc. (ACER) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Acer Therapeutics Inc. (ACER) closed at $2.39 in the latest trading session, marking a -0.83% move from the prior day.

Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics

by Zacks Equity Research

Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics are part of the Zacks Industry Outlook article.

Kinjel Shah headshot

5 Stocks to Buy as the Drug Industry Bets Big on Innovation

by Kinjel Shah

Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.

Are Medical Stocks Lagging Acer Therapeutics (ACER) This Year?

by Zacks Equity Research

Here is how Acer Therapeutics Inc. (ACER) and Syndax Pharmaceuticals (SNDX) have performed compared to their sector so far this year.

Acer Therapeutics Inc. (ACER) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Acer Therapeutics Inc. (ACER) closed the most recent trading day at $2.76, moving -0.36% from the previous trading session.

Biotech Stock Roundup: GILD's HIV Drug Approval, PRQR Surges on LLY Deal & More

by Zacks Equity Research

Updates from Gilead Sciences (GILD) and ProQR (PRQR) are the key highlights from the biotech sector during the past week.

PDS Biotech (PDSB) Up on Data From HPV-Positive Cancer Study

by Zacks Equity Research

A mid-stage study data shows that treatment with PDS Biotech's (PDSB) lead candidate in advanced HPV-positive cancer patients achieved a median overall survival of 21 months.

Minerva (NERV) Down; FDA Denies Review Schizophrenia Drug NDA

by Zacks Equity Research

Minerva (NERV) confirmed that the FDA's refuse-to-file letter on its regulatory filing, seeking approval for roluperidone, to treat symptoms of schizophrenia remains in effect.

Are Medical Stocks Lagging Acer Therapeutics (ACER) This Year?

by Zacks Equity Research

Here is how Acer Therapeutics Inc. (ACER) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Acer Therapeutics Inc. (ACER) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Acer Therapeutics Inc. (ACER) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

ACER Down Despite FDA Nod for Urea Cycle Disorders Drug

by Zacks Equity Research

The FDA approves Acer Therapeutics' (ACER) Olpruva (sodium phenylbutyrate) to treat certain patients with urea cycle disorders. Share price falls 33.3% following the announcement.

Is Acer Therapeutics (ACER) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Acer Therapeutics Inc. (ACER) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Talaris (TALS) Down on Patient Death From Renal Transplant Study

by Zacks Equity Research

Talaris Therapeutics (TALS) reports a patient death from its late-stage study evaluating its experimental drug, FCR001, in living donor kidney transplant patients. Stock down.

RedHill Biopharma (RDHL) Up on New Patent for COVID-19 Candidate

by Zacks Equity Research

RedHill Biopharma (RDHL) receives a new patent from the United States Patent and Trademark Office for its investigational COVID-19 candidate, opaganib, in COVID-19 patients with pneumonia. Stock up.

    Catalyst Pharmaceuticals (CPRX) Rallies 80.69% YTD: Here's Why

    by Zacks Equity Research

    Catalyst (CPRX) price rallies on FDA approval of the sNDA of its lead drug, Firdapse, approved to treat LEMS in patients above six years of age.